Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidaza in intermediate-2 and high risk MDS
NCT01305460Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jul 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Overall Response Rate at 4 months. Started Jul 2011; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01305460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01305460.